Market Closed -
Other stock markets
|
Pre-market 07:08:43 pm | |||
66.16 USD | -1.15% | 66.42 | +0.39% |
Apr. 17 | UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating | MT |
Apr. 15 | Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.33% | 83.46B | |
+27.97% | 676B | |
+23.58% | 554B | |
-7.02% | 349B | |
+14.85% | 318B | |
+6.25% | 291B | |
+2.96% | 210B | |
-0.41% | 204B | |
-10.02% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead's Trodelvy 'Significantly Improves' Overall Survival in Pre-Treated Metastatic Breast Cancer Patients